O-(叔丁基)-D-丝氨酸叔丁酯盐酸盐 | 179559-35-4

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 天然氨基酸及其衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: O-(叔丁基)-D-丝氨酸叔丁酯盐酸盐
• 中文别名: H-D-Ser(tBu)-OtBu・HCl；H-D-SER(TBU)-OTBU HCL
• 英文名称: (R)-2-amino-3-tert-butoxy-propionic acid tert-butyl ester hydrochloride
• 英文别名: O-(tert-butyl)-D-serine tert-butyl ester hydrochloride；tert-butyl O-(tert-butyl)-D-serinate hydrochloride；H-D-Ser(tBu)-OtBu hydrochloride；H-D-Ser(tBu)-OtBu HCl；tert-butyl (2R)-2-amino-3-[(2-methylpropan-2-yl)oxy]propanoate;hydrochloride
• CAS: 179559-35-4
• 化学式: C₁₁H₂₃NO₃*ClH
• 分子量: 253.769
• InChiKey: RDWZQVGVBTYCBD-DDWIOCJRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.89
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  61.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储温度应保持在0-5°C范围内。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: H-D-Ser(tbu)-otbu hcl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: H-D-Ser(tbu)-otbu hcl
CAS number: 179559-35-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H23NO3.ClH
Molecular weight: 253.8

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-氯-4-羟基异喹啉-3-羧酸 、 O-(叔丁基)-D-丝氨酸叔丁酯盐酸盐 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 40.0h， 生成 (R)-3-tert-Butoxy-2-[(1-chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-propionic acid tert-butyl ester
  参考文献：
  名称：

  Novel nitrogen-containing heteroaryl compounds and methods of use thereof

  摘要：

  本发明涉及适用于介导缺氧诱导因子和治疗与促红细胞生成素相关疾病的化合物，通过在体外和体内增加内源性促红细胞生成素来实现。

  公开号：

  US20040254215A1

文献信息

• Chemical compounds
  申请人：——

  公开号：US20040067933A1

  公开（公告）日：2004-04-08

  The present invention relates to compounds of the formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described. 1

  本发明涉及式(I)的化合物：（其中变量团如所定义）药用可接受的盐、溶剂化物、这些盐的溶剂化物以及前药及其作为回肠胆酸转运(IBAT)抑制剂用于治疗高脂血症的用途。还描述了它们的制造过程和包含它们的药物组合物。
• [EN] DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY<br/>[FR] DERIVES DIPHENYLAZETIDINONE A ACTIVITE INHIBITRICE DE L'ABSORPTION DU CHOLESTEROL
  申请人：ASTRAZENECA AB

  公开号：WO2005061452A1

  公开（公告）日：2005-07-07

  Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

  化合物的结构式（其中变量基团如定义所示）及其药学上可接受的盐、溶剂合物、该类盐的溶剂合物和它们的前药，以及它们作为治疗高脂血症的胆固醇吸收抑制剂的用途被描述。还描述了它们的制备方法和含有它们的药物组合物。
• Design of Low Molecular Weight Hematoregulatory Agents from the Structure−Activity Relationship of a Dimeric Pentapeptide
  作者：Alan S. Cuthbertson、Mette Husbyn、May Engebretsen、Michael Hartmann、Meinolf Lange、Jessie Sandosham、Peter M. Fischer、Hege Fjerdingstad、Dagfinn Løvhaug

  DOI：10.1021/jm9702443

  日期：1997.8.1

  cystine-dimerized peptide pGlu-Glu-Asp-Cys-Lys-OH, where the disulfide bond has been replaced by an isosteric dicarba bridge. The structure-activity relationship (SAR) of a series of analogues incorporating replacements at positions 1 and 2 of peptide 1 led to the design of active conformationally constrained cyclic peptides (12, 13). Ring closure was achieved by cyclization of the N-terminal amino

  我们在这里报告，一类新的简单的半规化半肽，正式从胱氨酸二聚肽pGlu-Glu-Asp-Cys-Lys-OH衍生而来，其中二硫键已被等位双卡巴桥所取代。一系列类似物在肽1的位置1和2处引入取代基的结构-活性关系（SAR）导致了活性构象受约束的环状肽的设计（12、13）。通过使用吡嗪-2，3-二羧酸使肽2的2位上的N-末端氨基环化来实现闭环。随后从活性环肽中切除了假定的C端支架结构域，结果发现了一类新的以化合物16为例的低分子量凝血调节剂。这种半肽类似物 包含两个通过酰胺键与吡嗪-2，3-二羧酸的酸基相连的D-Ser残基的生物活性与先导肽1相当。对这些新型化合物观察到的生物学活性的立体化学要求进行了研究。此外，化合物16在基质细胞培养物中诱导的造血协同活性被已知能中和1的放血调节作用的抗体阻断，这表明了一个共同的机制终点。以16为代表的类别的化合物可以形成在免疫调节领域内开发新型治疗剂的基础。
• [EN] NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN<br/>[FR] COMPOSES HETEROARYLIQUES CONTENANT DE L'AZOTE ET LEUR UTILISATION DANS L'AUGMENTATION DE L'ERYTHROPOIETINE ENDOGENE
  申请人：FIBROGEN INC

  公开号：WO2004108681A1

  公开（公告）日：2004-12-16

  The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.

  本发明涉及一种适用于介导缺氧诱导因子和治疗与促红细胞生成素相关疾病的化合物，通过在体外和体内增加内源性促红细胞生成素。
• [EN] CHEMICAL COMPOUNDS<br/>[FR] 1,5-BENZOTHIAZEPINES ET LEUR UTILISATION EN TANT QU'AGENTS ANTIHYPERLIPIDEMIE
  申请人：ASTRAZENECA AB

  公开号：WO2002050051A1

  公开（公告）日：2002-06-27

  The present invention relates to compounds of the formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.

  本发明涉及化合物的公式（I）（其中变量基团如定义），药学上可接受的盐，这些盐的溶剂，这些盐的溶剂和它们的前药，以及它们作为回肠胆汁酸转运（IBAT）抑制剂用于治疗高脂血症的用途。还描述了它们的制造过程和含有它们的制药组合物。